Treatment strategies for advanced pancreatic ductal adenocarcinoma (PDAC) continue to evolve, with growing emphasis on clinical trials, biomarker-driven care, and emerging targeted therapies.
Current frontline treatment remains chemotherapy-based. Patients with lower performance status are typically treated with gemcitabine alone, while fitter patients may receive combination regimens such as NALIRIFOX, FOLFIRINOX, or gemcitabine plus nab-paclitaxel. Physicians also carefully plan treatment sequencing to maximize the benefits of later-line therapies.
Because PDAC has a poor prognosis, with a five-year survival rate of about 13% and only 3% for metastatic disease, many clinicians favor early enrollment in clinical trials. Liquid biopsies and rapid next-generation sequencing help identify actionable biomarkers and match patients to targeted studies without delaying treatment.
KRAS inhibitors, including daraxonrasib, are emerging as a promising new option. These oral therapies have shown disease control rates of roughly 85% to 90%, helping stabilize tumors, preserve organ function, reduce symptoms, and improve quality of life. Researchers are now investigating their use in earlier disease settings to increase the number of patients eligible for surgery.